RxDoctor Payments Data

Victoria Okorie-Anochie

Psychiatric/Mental Health · Aberdeen, MDNPI 1770848939

Payments from drug & device makers

$1,793in general payments, 2019–2025

Across 79 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$407
  • Neurocrine Biosciences, Inc.$270
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$269
  • Takeda Pharmaceuticals U.S.A., Inc.$171
  • Alkermes, Inc.$157
  • Johnson & Johnson$99
  • plus $421 from 7 others

What the payments were for

  • Food & beverage$1,793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,793 in reported general payments places this provider in the 80th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$20,411
Medicare patients
29
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$189,777
Aripiprazole24$2,746
Divalproex Sodium ErDivalproex Sodium25$1,169
Ziprasidone Hcl17$871
Lurasidone Hcl23$674
Quetiapine Fumarate63$627
Risperidone47$452
Bupropion XlBupropion Hcl33$441
Olanzapine12$390
Duloxetine Hcl11$367
Gabapentin26$239
Hydroxyzine Pamoate18$176
Lamotrigine23$162
Trazodone Hcl49$130
Escitalopram Oxalate15$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$270$189,77723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Aberdeen

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →